Special Issue

Gram-Negative Bloodstream Infections

Message from the Guest Editor

This special issue aims to highlight the recent advancements in the pathogenesis, epidemiology, diagnosis, and antimicrobial management of Gram-negative bloodstream infections. The morbidity and mortality of Gram-negative bloodstream infections have heavy burden on the general public and special populations such as immune compromised hosts. Increasing antimicrobial resistance rates limit both empirical and definitive antimicrobial treatment options. Utilization of novel antimicrobial agents and cutting-edge treatment strategies through experimental and clinical therapeutics may improve clinical outcomes and advance this filed. Evolution of rapid diagnostics for early identification of bloodstream isolates as well as genotypic and phenotypic antimicrobial susceptibility testing provide opportunities for clinicians and researchers and hope for patients in a better future.

Keywords: Bloodstream infections; sepsis; antibiotic resistance; Gram-negative bacteria

Guest Editor

Prof. Dr. Majdi N. Al-Hasan

School of Medicine, University of South Carolina, Columbia, SC 29208, USA

Deadline for manuscript submissions

closed (15 April 2020)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/29027

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI